Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Seipel

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
International Journal of Molecular Sciences|October 29, 2025
Clinical Impact of LAG3 Single-Nucleotide Polymorphism in DLBCL Treated with CAR-T Cell TherapyKatja Seipel, Sophia Maria Spahr, Inna Shaforostova, et al.
Current Issues in Molecular Biology|August 28, 2024
Rising Prevalence of Low-Frequency <i>PPM1D</i> Gene Mutations after Second HDCT in Multiple MyelomaKatja Seipel, Nuria Z Veglio, Henning Nilius, et al.
Cancers|May 28, 2022
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell TherapyVera Rentsch, Katja Seipel, Yara Banz, et al.
Current Issues in Molecular Biology|August 27, 2025
Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell TherapyAlexa Burger, Ulrike Bacher, Michele Hoffmann, et al.
Journal of Clinical Medicine|February 27, 2026
AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab EraJulia Bee, Inna Shaforostova, Michèle Hoffmann, et al.
Cancers|March 28, 2026
Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with GlofitamabMaeva Ullmann, Katja Seipel, Henning Nilius, et al.
Leukemia & Lymphoma|October 14, 2016
Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacyJasmin Stettler, Urban Novak, Gabriela M Baerlocher, et al.
Current Oncology (Toronto, Ont.)|December 22, 2023
Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell LymphomaKatja Seipel, Michèle Frey, Henning Nilius, et al.
Current Issues in Molecular Biology|January 30, 2026
Elevated Allele Frequency and Male-Predominance of a Common <i>LAG3</i> Germline Variant in Multiple MyelomaKatja Seipel, Alina Mena, Pinar Horum, et al.
Biomedicines|June 26, 2026
Influence of <i>PPM1D</i> Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma PatientsElena Fiori, Martina Bertschinger, Ulrike Bacher, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
International Journal of Molecular Sciences|October 29, 2025
Clinical Impact of LAG3 Single-Nucleotide Polymorphism in DLBCL Treated with CAR-T Cell TherapyKatja Seipel, Sophia Maria Spahr, Inna Shaforostova, et al.
Current Issues in Molecular Biology|August 28, 2024
Rising Prevalence of Low-Frequency <i>PPM1D</i> Gene Mutations after Second HDCT in Multiple MyelomaKatja Seipel, Nuria Z Veglio, Henning Nilius, et al.
Cancers|May 28, 2022
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell TherapyVera Rentsch, Katja Seipel, Yara Banz, et al.
Current Issues in Molecular Biology|August 27, 2025
Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell TherapyAlexa Burger, Ulrike Bacher, Michele Hoffmann, et al.
Journal of Clinical Medicine|February 27, 2026
AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab EraJulia Bee, Inna Shaforostova, Michèle Hoffmann, et al.
Cancers|March 28, 2026
Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with GlofitamabMaeva Ullmann, Katja Seipel, Henning Nilius, et al.
Leukemia & Lymphoma|October 14, 2016
Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacyJasmin Stettler, Urban Novak, Gabriela M Baerlocher, et al.
Current Oncology (Toronto, Ont.)|December 22, 2023
Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell LymphomaKatja Seipel, Michèle Frey, Henning Nilius, et al.
Current Issues in Molecular Biology|January 30, 2026
Elevated Allele Frequency and Male-Predominance of a Common <i>LAG3</i> Germline Variant in Multiple MyelomaKatja Seipel, Alina Mena, Pinar Horum, et al.
Biomedicines|June 26, 2026
Influence of <i>PPM1D</i> Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma PatientsElena Fiori, Martina Bertschinger, Ulrike Bacher, et al.
Pageof 8